Five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia.

The complete list of Editas Medicine presentations is below.

 

American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, May 11-15

Oral Presentation:

Title: Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C

Session Date and Time: Thursday, May 14, 3:30 p.m. – 5:00 p.m. EDT

Session Title: Gene Therapy for Cardiovascular Diseases

Presentation Room: 206AB

Final Abstract Number: 380

 

Poster Presentations:

Title: Pharmacokinetics and Pharmacodynamics of In Vivo Gene Editing Therapy for Lowering LDL-C in Mice

Session Date and Time: Thursday, May 14, 5:00 p.m. – 6:30 p.m. EDT

Session Title: Thursday Poster Reception

Presentation Room: Exhibit and Poster Hall

Final Abstract Number: 3423

Title: In Vivo CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model

Session Date and Time: Wednesday, May 13, 5:00 p.m. – 6:30 p.m. EDT

Session Title: Wednesday Poster Reception

Presentation Room: Exhibit and Poster Hall

Final Abstract Number: 2324

 

TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, May 11-14

Oral Presentation:

Title: Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease

Session Date and Time: Wednesday, May 13, 8:30 a.m. – 9:00 a.m. EDT

Session Title: mRNA & Genome Editing: Technology & Applications

 

94th European Atherosclerosis Society (EAS) Congress, May 24-27

Oral Presentation:

Title: A Transformative In Vivo CRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human Primates

Session Date and Time: Monday, May 25, 3:45 p.m. – 5:15 p.m. EET/9:45 a.m. – 11:15 a.m. EDT

Session Title: New Pathways for Lipid and Lipoprotein Metabolism

Presentation Room: Nana Hall

Final Abstract Number: 159

Abstracts can be accessed on the conference websites as they become available, and the presentations will be posted on the Editas Medicine website during the conferences.